Presse & Publications

Presse

https://www.alcediag-alcen.com/wp-content/uploads/2023/10/ALCEDIAG-laureat.jpeg
Award | octobre 09, 2023

Finalist list of the European Lifestars Awards – Celebrating Life Science eXecutives & their partners!

https://www.alcediag-alcen.com/wp-content/uploads/2024/01/PHOTO-2023-04-04-14-26-47.jpg
Award | mars 28, 2023

We won the Medical Diagnostic trophy at the 2nd edition of the « Healthtech awards » organised by France Biotech!

https://www.alcediag-alcen.com/wp-content/uploads/2023/03/SynLab-logo.svg
Communiqué de presse | mars 27, 2023

ALCEDIAG and SYNLAB join forces in Europe to fight diagnostic delay of bipolar disorder with the EDIT-B™ test

https://www.alcediag-alcen.com/wp-content/uploads/2024/01/Ouest-France-image.jpeg
News | novembre 18, 2022

OUEST-FRANCE À Montpellier, une start-up développe un test pour diagnostiquer la bipolarité

https://www.alcediag-alcen.com/wp-content/uploads/2024/01/ALCEDIAG-1.png
News | juillet 12, 2022

ALCEDIAG Announces the Inclusion of the First Patient in clinical validation study for EDIT-B test: an aid for differential diagnosis of bipolar disorder, based on RNA editing blood biomarkers

Publications scientifiques

Translational Psychiatry | août 20, 2016

In vitro screening for drug-induced depression and/or suicidal adverse effects: a new toxicogenomic assay based on CE-SSCP analysis of HTR2C mRNA editing in SH-SY5Y cells

D Weissmann, S van der Laan, MD Underwood, N Salvetat, L Cavarec, L Vincent, F Molina, JJ Mann, V Arango and JF Pujol

Download PDF